Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma | Zendy

Marie PerierMuzet | Zendy; Elodie Gatt | Zendy; Julien Péron | Zendy; Claire Falandry | Zendy; Mona AminiAdlé | Zendy; L. Thomas | Zendy; Stéphane Dalle | Zendy; Amélie Boespflug | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma

Author(s) -

Marie PerierMuzet,

Elodie Gatt,

Julien Péron,

Claire Falandry,

Mona AminiAdlé,

L. Thomas,

Stéphane Dalle,

Amélie Boespflug

Publication year - 2017

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2017.4584

Subject(s) - medicine , ipilimumab , nivolumab , pembrolizumab , cohort , immunotherapy , melanoma , adverse effect , retrospective cohort study , progression free survival , oncology , overall survival , cancer , cancer research

Melanoma treatment has been revolutionized with the development of immune-based therapies that offer durable clinical responses in a subset of patients. Clinical outcomes after treatment by immunotherapy can be influenced by the host's immune system. The immune system is modified with age by age-related immune dysfunction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research